 |
Hold (2.33 out of 4)
100th percentile
|
|
|
 Preferred Stock Offerings
By Preferred Stock Channel Staff, updated Friday, April 19, 11:10 PM
Slide #142. Trillium Therapeutics Inc. — Preferred Stock Offering
| Company: |
Trillium Therapeutics Inc. (TRIL) |
| Date announced: |
1/22/2020 |
| Shares Offered: |
1,250,000 |
| Date of Pricing: |
1/23/2020 |
| Price Per Share: |
$2.75 |
| Preferred Stock Offering Details: |
Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has commenced a public offering of common shares (the "Common Shares") of the Company and Series II Non-Voting Convertible First Preferred Shares (the "Series II First Preferred Shares") of the Company (the "Offering"). In addition, Trillium intends to grant the underwriters a 30-day option to purchase up to an additional amount of Common Shares equal to 15% of the Common Shares and Series II First Preferred Shares offered in the Offering. -updated 1/23- Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has priced its previously announced underwritten public offering of 35,731,818 common shares (the "Common Shares") of the Company and 1,250,000 Series II Non-Voting Convertible First Preferred Shares (the "Series II First Preferred Shares") of the Company (the "Offering"). The Common Shares are being sold at a public offering price of US$2.75 per Common Share and the Series II First Preferred Shares are being sold at a public offering price of US$2.75 per Series II First Preferred Share. In connection with the Offering, Trillium has granted the underwriters a 30-day option to purchase up to an additional 5,547,272 Common Shares. |
Trillium Therapeutics is a clinical stage immuno-oncology company developing therapies for the treatment of cancer. Co.'s primary program, TTI-621, is a SIRPaFc fusion protein that consists of the extracellular CD47-binding domain of human signal regulatory protein alpha (SIRPa) linked to the Fc region of a human immunoglobulin G1 (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory signal. Co. is also developing a second SIRPaFc fusion protein, TTI-622, which consists of the extracellular CD47-binding domain of human SIRPa linked to a human immunoglobulin G4 Fc region, which has a decreased ability to engage Fc receptors than an IgG1 Fc.
 Open the TRIL Page at Preferred Stock Channel »
Open the TRIL Page at Preferred Stock Channel (in a new window) »
|
|
Free TRIL Email Alerts:
